ArticleAngewandte Chemie (International ed. in English)2026
Chemically Masked aPD-L1-Sialidase Conjugate for Tumor-Specific Desialylation and Immunotherapy.
Article in Angewandte Chemie (International ed. in English), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Biomaterial engineering of the tumor glycocalyx for cancer immunotherapy.Materials today. Bio · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Immune checkpoint inhibitors (ICIs) have revolutionized cancer immunotherapy, yet their clinical efficacy remains limited by low response rates and frequent immune-related adverse events caused by on-target off-tumor toxicity. In this study, we developed a chemically masked anti-PD-L1 nanobody-sialidase conjugate (CAPS) to achieve precise control of protein function. The chemical mask is installed via site-specific PEGylation following the incorporation of a genetically encoded non-canonical amino acid, and is selectively removed by MMP2 within the tumor microenvironment to restore function locally. This design achieves "one construct, three functions" by enabling simultaneous control over nanobody affinity, desialylation activity, and tumor tissue penetration, thereby enhancing tumor specificity and concurrently disrupting the PD-1/PD-L1 and Sialoglycan/Siglec axes. Compared to the unmasked control (anti-PD-L1 nanobody-sialidase, APS), CAPS exhibited a 144-fold extension in systemic half-life and a 9.3-fold increase in tumor-site accumulation. Collectively, CAPS demonstrated superior antitumor efficacy, enhanced immune activation, and an improved safety profile in mouse models of ICI-resistant colorectal cancer. These findings support CAPS as a new class of glyco-ICIs and offer a promising therapeutic strategy to overcome the limitations of current ICIs by enhancing therapeutic efficacy while minimizing on-target off-tumor toxicity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.